Nonmotor symptoms of Parkinson's disease

Expert Review of Neurotherapeutics

Volumn 6, Issue 12, 2006, Pages 1811-1822

  Zesiewicz, Theresa A ^a   Sullivan, Kelly L ^a   Hauser, Robert A ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Autonomic dysfunction; Cognition; Mood disorders; Nonmotor symptoms; Parkinson's disease

Indexed keywords

ANTICONVULSIVE AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; DARIFENACIN; DOCUSATE SODIUM; DOPAMINE RECEPTOR STIMULATING AGENT; ESZOPICLONE; FLUDROCORTISONE; LEVODOPA; MACROGOL; MIDODRINE; MODAFINIL; MONOAMINE OXIDASE INHIBITOR; MOSAPRIDE CITRATE; OPIATE; OXYBUTYNIN; PRAMIPEXOLE; PRO PANTHEL; PROPANTHELINE BROMIDE; QUETIAPINE; ROPINIROLE; SEROTONIN UPTAKE INHIBITOR; SILDENAFIL; SOLIFENACIN; TEGASEROD; TOLTERODINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZALEPLON; ZOLPIDEM; ZOLPIDEM TARTRATE;

ADJUVANT THERAPY; ANXIETY; APATHY; AUTONOMIC DYSFUNCTION; BEHAVIOR DISORDER; COGNITIVE DEFECT; CONSTIPATION; DAYTIME SOMNOLENCE; DEMENTIA; DEPRESSION; DRUG DEPENDENCE; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG FORMULATION; DYSPHAGIA; EVALUATION; FATIGUE; HEALTH CARE PERSONNEL; HUMAN; HYPERSEXUALITY; MONOTHERAPY; MOOD DISORDER; ORTHOSTATIC HYPOTENSION; PAIN; PARKINSON DISEASE; PATHOGENESIS; PSYCHOSIS; QUESTIONNAIRE; RATING SCALE; RECOMMENDED DRUG DOSE; RESTLESS LEGS SYNDROME; REVIEW; SCREENING; SEXUAL DYSFUNCTION; SLEEP APNEA SYNDROME; SLEEP DISORDER; SMELLING DISORDER; SOMNOLENCE; SYMPTOMATOLOGY; URINARY DYSFUNCTION; VISUAL DISORDER; XEROSTOMIA;

AUTONOMIC NERVOUS SYSTEM DISEASES; COGNITION DISORDERS; HEALTH STATUS INDICATORS; HUMANS; MOOD DISORDERS; MOVEMENT DISORDERS; PARKINSON DISEASE; QUESTIONNAIRES; SLEEP DISORDERS;

EID: 33845895997     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.6.12.1811     Document Type: Review

References (131)

1. Parkinson J. An essay on the shaking palsy. 1817. [reprint of monograph published by Sherwood, Neely, and Jones, London]. J. Neuropsychiatry Clin. Neurosci. 14, 223-236 (2002).
2. Cummings JL. Depression and Parkinson's disease: a review. Am. J. Psychiatry 149, 443-454 (1992).
3. Lees AJ, Blackburn NA, Campbell VL. The nighttime problems of Parkinson's disease. Clin. Neuropharmacol. 11(6), 512-519 (1988).
4. Slawek J, Derejko M, Lass P. Factors affecting the quality of life of patients with idiopathic Parkinson's disease - a cross-sectional study in an outpatient clinic attendees. Parkinsonism Relat. Disord. 11(7), 465-468 (2005).
5. Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease. J. Am. Geriatr. Soc. 52(5), 784-788 (2004).
6. Parkinson Study Group. Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology 60(11), 1756-1761 (2003). • Examined the long-term outcomes of Parkinson's disease (PD) patients with psychosis.
7. Shulman LM, Taback RL, Bean J, Weiner WJ. Comorbidity of the nonmotor symptoms of Parkinson's disease. Mov. Disord. 16(3), 507-510 (2001).
8. Shulman LM, Taback RL, Rabinstein AA, Weiner WJ. Non-recognition of depression and other non-motor symptoms in Parkinson's disease. Parkinsonism Relat. Disord. 8(3), 193-197 (2002).
9. Sullivan KL, Ward CL, Hauser RA, Dunne PB, Zesiewicz TA. Prevalence and treatment of non-motor symptoms in Parkinson's disease. Presented at: 58th American Academy of Neurology Annual meeting. San Diego, CA, USA 1-8 April P04, 031 (2006).
10. Chaudhuri KR, Martinez-Martin P, Schapira AHV et al. An international multicentre pilot study of the first comprehensive self-completed non-motor symptoms questionnaire for Parkinson's disease: The NMSQuest study. Mov. Disord. (2006) (In Press). •• Assessed the feasibility, validity and acceptability of the nonmotor questionnaire for PD (NMSQuest) screening questionnaire which was found to be a comprehensive tool to assess nonmotor symptoms.
11. Goetz CG, Fahn S, Martinez-Martin P et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDSUPDRS): Process, format, and clinimetric testing plan. Mov. Disord. (2006) (Epub ahead of print). • Revision of the Unified Parkinson's Disease Rating Scale (UPDRS) will include an expanded section assessing nonmotor symptoms.
12. Awerbuch GI, Sandyk R. Autonomic functions in the early stages of Parkinson's disease. Int. J. Neurosci. 64(1-4), 7-14 (1992).
13. Kremer HP. The hypothalamic lateral tuberal nucleus: normal anatomy and changes in neurological diseases. Prog. Brain Res. 93, 249-261 (1992).
14. Qualman SJ, Haupt HM, Yang P, Hamilton SR. Esophageal Lewy bodies associate with ganglion cell loss in achalasia. Similarity to Parkinson's disease. Gastroenterology 87, 848-856 (1984).
15. McTavish D, Goa KL. Midodrine: a review of its pharmacological properties and therapeutic use in orthostatic hypotension and secondary hypotensive disorders. Drugs 38, 757-777 (1989).
16. Pittner H, Stormann H, Enzenhofer R. Pharmacodynamic actions of midodrine, a new alpha-adrenergic stimulating agent, and its main metabolite, ST 1059. Arzneimittelforschung 26, 2145-2154 (1976).
17. Zachariah PK, Bloedow DC, Moyer TP, Sheps SG, Schirger A et al. Pharmacodynamics of midodrine, an antihypotensive agent. Clin. Pharmacol. Ther. 39, 586-591 (1986).
18. Kaufman H, Brannan T, Krakoff L, Yahr MD, Mandeli J. Treatment of orthostatic hypotension due to autonomic failure with a peripheral alpha-adrenergic agonist (midodrine). Neurology 38, 951-956 (1988).
19. Jankovic J, Gilden JL, Hiner BC, Kaufman H, Brown DC. Neurogenic orthostatic hypotension: a double-blind placebo-controlled study with midodrine. Am J Med 95, 38-48 (1993). • Double-blind, placebo-controlled study of midodrine in 97 patients with orthostatic hypotension due to autonomic failure.
20. Jost WH, Schimrigk K. Constipation in Parkinson's disease. Klinische Wochenschrift 69, 906-909 (1991).
21. Kupsky WJ, Grimes MM, Sweeting J, Bertsch R, Cote LJ. Parkinson's disease and megacolon: concentric hyaline inclusions (Lewy bodies) in enteric ganglion cells. Neurology 37(7), 1253-1255 (1987).
22. Mathers SE, Kempster PA, Swash M, Lees AJ. Constipation and paradoxical puborectalis contraction in anismus and Parkinson's disease: a dystonic phenomenon? J. Neurol. Neurosurg. Psychiatry 51(12), 1503-1507 (1988).
23. Sullivan KL, Staffetti JF, Hauser RA et al. Tegaserod (Zelnorm) for the treatment of constipation in Parkinson's disease. Mov. Disord. 21(1) 115-116 (2005). • Double-blind, placebo-controlled study of tegaserod in PD patients with constipation.
24. Liu Z, Sakakibara R, Odaka T, Uchiyama T et al. Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients. Mov. Disord. 20(6), 680-686 (2005).
25. Sakakibara R, Shinotoh H, Uchiyama T et al. Questionnaire-based assessment of pelvic organ dysfunction in Parkinson's disease. Auton. Neurosci. 92(1-2), 76-85 (2001).
26. Coates C, Bakheit AM. Dysphagia in Parkinson's disease. Eur. Neurol. 38(1), 49-52 (1997).
27. Wang SJ, Chia LG, Hsu CY, Lin WY, Kao CH, Yeh SH. Dysphagia in Parkinson's disease. Assessment by solid phase radionuclide scintigraphy. Clin. Nuc. Med. 19, 405-407 (1994).
28. Winge K, Fowler CJ. Bladder dysfunction in Parkinsonism: mechanisms, prevalence, symptoms, and management. Mov. Disord. 21(6), 737-745 (2006).
29. Campos-Sousa RN, Quagliato E, da Silva BB, de Carvalho RM Jr, Ribeiro SC, de Carvalho DF. Urinary symptoms in Parkinson's disease: prevalence and associated factors. Arq. Neuropsiquiatr. 61(2B), 359-363 (2003).
30. Vesicare® Package Insert. GlaxoSmithKline, Research Triangle Park, NC, USA.
31. Enablex® Package Insert. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
32. Papatsoris AG, Deliveliotis C, Singer C, Papapetropoulos S. Erectile dysfunction in Parkinson's disease. Urology 67(3), 447-451 (2006).
33. Hobson P, Islam W, Roberts S, Adhiyman V, Meara J. The risk of bladder and autonomic dysfunction in a community cohort of Parkinson's disease patients and normal controls. Parkinsonism Relat. Disord. 10(2), 67-71 (2003).
34. Nehra A, Moreland RB. Neurologic erectile dysfunction. Urol. Clin. North Am. 28(2), 289-308 (2001).
35. Zesiewicz TA, Helal M, Hauser RA. Sildenafil Citrate (Viagra) for the treatment of erectile dysfunction in men with Parkinson's disease. Mov. Disord. 15, 305-308 (2000). • Open-label study assessed the effects of sildenafil citrate inten men with PD and erectile dysfunction.
36. Pohanka M, Kanovsky P, Bares M, Pulkrabek J, Rektor I. The long-lasting improvement of sexual dysfunction in patients with advanced, fluctuating Parkinson's disease induced by pergolide: evidence from the results of an open, prospective, one-year trial. Parkinsonism Relat. Disord. 11(8), 509-512 (2005). • Assessed the effects of pergolide used as adjunct medication in 14 men with PD and sexual dysfunction.
37. Vogel HP, Schiffter R. Hypersexuality - a complication of dopaminergic therapy in Parkinson's disease. Pharmacopsychiatria 16(4), 107-110 (1983).
38. Voon V, Hassan K, Zurowski M et al. Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology 67(7), 1254-1257 (2006).
39. Klos KJ, Bower JH, Josephs KA, Matsumoto JY, Ahlskog JE. Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat. Disord. 6, 381-386 (2005).
40. Romito LM, Raja M, Daniele A et al. Transient mania with hypersexuality after surgery for high frequency stimulation of the subthalamic nucleus in Parkinson's disease. Mov. Disord. 17(6), 1371-1374 (2002).
41. Ferreira JJ, Desboeuf K, Galitzky M et al. Sleep disruption, daytime somnolence and 'sleep attacks' in Parkinson's disease: a clinical survey in PD patients and age-matched healthy volunteers. Eur. J. Neurol. 13(3), 209-214 (2006).
42. Dhawan V, Dhoat S, Williams AJ et al. The range and nature of sleep dysfunction in untreated Parkinson's disease (PD). A comparative controlled clinical study using the Parkinson's disease sleep scale and selective polysomnography. J. Neurol. Sci. 248(1-2), 158-62 (2006). • Examined sleep dysfunction in 25 men with untreated PD compared with 34 healthy male controls.
43. Chaudhuri KR, Martinez-Martin P. Clinical assessment of nocturnal disability in Parkinson's disease: the Parkinson's Disease Sleep Scale. Neurology 63(8 Suppl. 3), S17-S20 (2004).
44. Borek LL, Kohn R, Friedman JH. Mood and sleep in Parkinson's disease. J. Clin. Psychiatry 67(6), 958-963 (2006).
45. Gomez-Esteban JC, Zarranz JJ, Lezcano E et al. Sleep complaints and their relation with drug treatment in patients suffering from Parkinson's disease. Mov. Disord. 21(7), 983-988 (2006).
46. Juri C, Chana P, Tapia J, Kunstmann C, Parrao T. Quetiapine for insomnia in Parkinson disease: results from an open-label trial. Clin. Neuropharmacol. 28(4), 185-187 (2005).
47. Homan CN, Wenzyl K, Suppan M et al. Sleep attacks after acute administration of apomorphine. Mov. Disord. 15(Suppl. 3), 108 (2000).
48. Arnulf I, Bonnett AM, Damier P et al. Hallucinations, REM sleep, and Parkinson's disease. Neurology 55, 281-288 (2000).
49. Hobson DE, Lang AE, Martin WR et al. Excessive daytime sleepiness and sudden-onset sleep in Parkinson's disease. A survey by the Canadian Movement Disorders Group. JAMA 287, 455-463 (2002).
50. Gjerstad MD, Alves G, Wentzel-Larsen T, Aarsland D, Larsen JP. Excessive daytime sleepiness in Parkinson disease: is it the drugs or the disease? Neurology 67(5), 853-888 (2006).
51. Shpirer I, Miniovitz A, Klein C et al. Excessive daytime sleepiness in patients with Parkinson's disease: a polysomnography study. Mov. Disord. 9, 1432-1438 (2006).
52. Ondo WG, Dat Vuon G, Khan H et al. Daytime sleepiness and other sleep disorders in Parkinson's disease. Neurology 57, 1392-1396 (2001). •• Survey of the prevalence, severity and clinical correlates of sleep disorders in a cohort of patients with PD.
53. Lee MS, Rinne JO, Marsden CD. The pedunculopontine nucleus: its role in the genesis of movement disorders. Yonsei Med. J. 41, 167-184 (2000).
54. Etminan M, Samii A, Takkouche B, Rochon PA. Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease: a meta-analysis of randomized controlled trials. Drug Saf. 24(11), 863-868 (2001). • Meta-analysis somnolence in four trials of patients taking pramipexole or ropinirole compared with placebo.
55. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson's disease. A randomized controlled trial. JAMA 284, 1931-1938 (2000). • Multicenter, parallel-group, double-blind, randomized controlled trial compares the development of dopaminergic motor complications in PD patients initially treated with pramipexole versus levodopa.
56. Hogl B, Saletu M, Brandauer E et al. Modafinil for the treatment of daytime Sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep 25(8), 905-909 (2002). • Double-blind, randomized, placebo-controlled crossover study of 15 idiopathic PD patients with daytime sleepiness.
57. Adler CH, Caviness JN, Hentz JG et al. Randomized trial of modafinil for treating subjective daytime Sleepiness in patients with Parkinson's disease. Mov. Disord. 18(3), 287-293 (2003). • Single-site, randomized, double-blind, placebo-controlled crossover study of modafinil in treating excessive daytime sleepiness in 21 PD patients.
58. Hauser RA, Wahba MN, Zesiewicz TA, McDowell Anderson W. Modafinil treatment of pramipexole-associated somnolence. Mov. Disord. 15, 1269-1271 (2000).
59. Frucht S, Rogers JD, Green PE et al. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 52, 1908-1910 (1999).
60. Arnulf I. Excessive daytime sleepiness in parkinsonism. Sleep Med. Rev. 9(3), 185-200 (2005).
61. Brodsky MA, Godbold J, Olanow CW. sleepiness in Parkinson's diseasea. Parkinsonism Relat. Disord. 7, S93 (2001).
62. Olanow CW, Schapria AH, Roth T. Waking up to sleep episodes in Parkinson's disease. Mov. Disord. 15(2), 212-215 (2000).
63. Ferreira JJ, Desboeuf K, Galitzky M et al. Sleep disruption, daytime somnolence and 'sleep attacks' in Parkinson's disease: a clinical survey in PD patients and age-matched healthy volunteers. Eur. J. Neurol. 13(3), 209-214 (2006). • Cross-sectional survey of 176 PD patients and 174 age-matched controls.
64. Homann CN, Wenzel K, Suppan K et al. Sleep attacks in patients taking dopamine agonists: review. Br. Med. J. 324, 1483-1487 (2002).
65. Frucht S, Roger JD, Green PE et al. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 52, 1908-1910 (1999). • Report of sleep attacks while driving in eight PD patients taking pramipexole and one taking ropinirole.
66. Hauser RA, Gauger L, McDowell Andersen W, Zesiewicz TA. Pramipexole-induced somnolence and episodes of daytime sleep. Mov. Disord. 15(4), 601-603 (2000).
67. Arnulf I, Konofal E, Merino-Andreu M et al. Parkinson's disease and sleepiness: an integral part of PD. Neurology 58, 1019-1024 (2002).
68. Beove BF, Silber MH, Ferman TJ et al. Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov. Disord. 16, 622-630 (2001).
69. Adler CH, Thorpy MJ. Sleep issues in Parkinson's disease. Neurology 64(Suppl. 3), S12-S20 (2005).
70. Comella CL, Tanner CM, Ristanovic RK. Polysomnographic sleep measures in Parkinson's disease patients with treatment-induced hallucinations. Ann. Neurol. 34, 710-714 (1993).
71. Ozekmekci S, Apaydin H, Kilic E. Clinical features of 35 patients with Parkinson's disease displaying REM behavior disorder. Clin. Neurol. Neurosurg. 107(4), 306-309 (2005).
72. Morrison AR. The pathophysiology of REM-sleep behavior disorder. Sleep 21, 446-449 (1998).
73. Ondo WG, Vuong KD, Jankovic J. Exploring the relationship between Parkinson disease and restless legs syndrome. Arch. Neurol. 59(3), 421-424 (2002).
74. Chesson AL Jr, Wise M, Davila D et al. Practice parameters for the treatment of restless legs syndrome and periodic limb movement disorder. An American Academy of Sleep Medicine Report. Standards of Practice Committee of the American Academy of Sleep Medicine. Sleep. 22(7), 961-968 (1999).
75. Nomura T, Inoue Y, Nakashima K. Clinical characteristics of restless legs syndrome in patients with Parkinson's disease. J. Neurol. Sci. 250(1-2), 39-44. (2006). • Assessed characteristics of restless legs syndrome (RLS) in 13 PD patients with RLS compared with 22 patients with idiopathic RLS.
76. Brown RG, Dittner A, Findley L, Wessely SC. The Parkinson fatigue scale. Parkinsonism Relat. Disord. 11(1), 49-55 (2005).
77. Friedman JH, Friedman H. Fatigue in Parkinson's disease: a nine-year follow-up. Mov. Disord. (2001) 16(6), 1120-1122.
78. Friedman J, Friedman H. Fatigue in Parkinson's disease. Neurology 43(10), 2016-2018 (1993).
79. Cummings JL. Depression and Parkinson's disease: a review. Am. J. Psychiatry 149, 443-454 (1992).
80. Ehmann TS, Beninger RJ, Gawal MJ, Riopelle RJ. Depressive symptoms in Parkinson's disease: a comparison with disabled control subjects. J. Geriatr. Psychiatry Neurol. 3(1), 3-9 (1990).
81. Gotham AM, Brown RG, Marsden CD. Depression in Parkinson's disease: a quantitative and qualitative analysis. J. Neurol. Neurosurg. Psychiatry 49, 381-389 (1986). • Assessed depressive symptoms in patients with PD compared with normal elderly subjects and patients with arthritis.
82. Celesia GC, Wanamaker WM. Psychiatric disturbances in Parkinson's disease. Dis. Nerv. Syst. 33, 577-583 (1972).
83. Mayeux R, Stern Y, Williams JBW, Cote L, Frantz A, Dyrenfurth I. Clinical and biochemical features of depression in Parkinson's disease. Am. J. Psychiatry 143, 756-759 (1986).
84. Mayeux R, Stern Y, Sano M, Williams JB, Cote LJ. The relationship of serotonin to depression in Parkinson's disease. Mov. Disord. 3, 237-244 (1988).
85. Andersen J, Aabro E, Gulmann N, Hjelmsted A, Pedersen HE. Anti-depressive treatment in Parkinson's disease: a controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-dopa. Acta Neurol. Scand. 52, 210-219 (1980). • Placebo-controlled trial of 19 PD patients with depressive symptoms evaluated the therapeutic effect of nortriptyline.
86. Laitenen L. Desipramine in treatment of Parkinson's disease. Acta Neurol. Scand. 45, 109-113 (1969). • Placebo-controlled study evaluated the effects of desipramine in patients with PD.
87. Goetz CG, Tanner CM, Klawans HL. Bupropion in Parkinson's disease. Neurology 34, 1092-1094 (1984). • Evaluated the effects of bupropion in 20 patients with PD.
88. Jansen-Steur ENH. Increase of Parkinson disability after fluoxetine medication. Neurology 43, 211-213 (1993). • Case-series of four patients with PD who were treated with fluoxetine.
89. Jimenez-Jimenez FJ, Tejeiro J, Martinez-Junquera G et al. Parkinsonism exacerbated by paroxetine. Neurology 44, 2406 (1994).
90. Hauser RA, Zesiewicz TA. Sertraline for the treatment of depression in Parkinson's disease. Mov. Disord. 12, 756-759 (1997). • Open-label pilot study of sertraline to treat depression in 15 PD patients with depression.
91. Weintraub D, Taraborelli D, Morales KH, Duda JE, Katz IR, Stern MB. Escitalopram for major depression in Parkinson's disease: an open-label, flexible-dosage study. J. Neuropsychiatry Clin. Neurosci. 18(3), 377-383 (2006). • Open-label study of escitalopram in 14 PD patients with major depression.
92. Weintraub D, Morales KH, Moberg PJ et al. Antidepressant studies in Parkinson's disease: a review and meta-analysis. Mov. Disord. 20(9), 1161-1169 (2005). • Evaluated effect sizes for antidepressant treatments and placebo in PD patients with depression compared with elderly depressed non-PD patients.
93. Sternbach H. The serotonin syndrome. Am. J. Psychiatry 148, 705-713 (1991).
94. Nirenberg DW, Semprebon M. The central nervous system serotonin syndrome. Clin. Pharmacol. Ther. 53(1), 84-88 (1993).
95. Tackley RM, Tregaskis B. Fatal disseminated intravascular coagulation following a monoamine oxidase inhibitor/tricyclic interaction. Anaesthesia 42, 760-763 (1987).
96. Corkeron MA. Serotonin syndrome - a potentially fatal complication of antidepressant therapy. Med. J. Austral. 163, 481-482 (1995).
97. Waters CH. Fluoxetine and selegiline - lack of significant interaction. Can. J. Neurol. 21, 259-261 (1994).
98. Richard IH, Kurlan R, Tanner C et al. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Parkinson Study Group. Neurology 48, 1070-1077 (1997).
99. Richard IH. Anxiety disorders in Parkinson's disease. Adv. Neurol. 96, 42-55 (2005).
100. Witjas T, Kaphan E, Azulay JP et al. Nonmotor flucutuations in Parkinson's disease: frequent and disabling. Neurology 59, 408-413 (2002).
101. Levy R, Dubois B. Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits. Cerebral Cortex 16, 916-928 (2006).
102. Levy ML, Cummings JL, Fairbanks LA et al. Apathy is not depression. J. Neuropsychiatry 10, 314-319 (1998).
103. Starkstein SE, Mayberg SE Preziosi TJ et al. Reliability, validity and clinical correlates of apathy in Parkinson's disease. J. Neuropsychiatry 4, 134-139 (1992).
104. Pluck GC, Brown RG. Apathy in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 73, 636-642 (2002).
105. Padala PR, Petty F, Bhatia SC. Methylphenidate may treat apathy independend of depression. Ann. Pharmacother. 39, 1947-1949 (2005).
106. Emre M. Dementia associated with Parkinson's disease. Lancet Neurol. 2(4), 229-237 (2003).
107. Aarsland D, AndersenK, Larsen J et al. Prevalence and characteristics of dementia in Parkinson's disease: an 8-year prospective study. Arch. Neurol. 60, 387-392 (2003).
108. Peran P, Rascol O, Demonet JF et al. Deficit of verb generation in nondemented patients with Parkinson's disease. Mov. Disord. 18, 150-156 (2003).
109. Agid Y, Ruberg M, Dubois B et al. Parkinson's disease and dementia. Clin. Neuropharm. 9, S22-S36 (1986).
110. Parashos SA, Maraganore DM, O'Brien PC, Rocca WA. Medical services utilization and prognosis in Parkinson disease: a population-based study. Mayo Clin. Proc. 77(9), 918-925 (2002).
111. McKeith IG, Galasko D, Kosaka K et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47(5), 1113-1124 (1996).
112. Ravina B, Putt M, Siderowf A et al. Donopezil for dementia in Parkinson's disease: a randomized, double-blind, placebo controlled, crossover study. J. Neurol. Neurosurg. Psychiatry 76(7), 934-939 (2005). • Randomized, double-blind, placebo-controlled, crossover study of donepezil in the treatment of dementia in 22 PD patients.
113. Emre M, Aarsland D, Albanese A et al. Rivastigmine for dementia associated with Parkinson's disease. N. Engl. J. Med. 351(24), 2509-2518 (2004). • Double-blind, randomized, placebo-controlled study evaluated the effects of rivastigmine in 541 patients with PD and mild-to-moderate dementia.
114. Poewe W, Wolters E, Emre M et al. EXPRESS Investigators. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study. Mov. Disord. 21(4), 456-461 (2006). • 48-week open-label study of rivastigmine in 334 patients with PD and dementia.
115. Ravina B, Putt M, Siderowf A et al. Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. J. Neurol. Neurosurg. Psychiatry 76(7), 934-999 (2005). • Randomized, double-blind, placebo-controlled, crossover study of donepezil in 22 subjects with PD and dementia.
116. Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. Int. J. Geriatr. Psychiatry 18(10), 937-941 (2003). • Open-label study of galantamine in 16 patients with PD and dementia.
117. Thanvi BR, Lo TC, Harsh DP. Psychosis in Parkinson's disease. Postgrad. Med. J. 81(960), 644-646 (2005).
118. Frieling H, Hillemacher T, Ziegenbein M, Neundorfer B, Bleich S. Treating dopamimetic psychosis in Parkinson's disease: Structured review and meta-analysis. Eur. Neuropsychopharmacol. 17(3), 165-171 (2006).
119. Merims D, Balas M, Peretz C, Shabtai H, Giladi N. Rater-blinded, prospective comparison: quetiapine versus clozapine for parkinson's disease psychosis. Clin. Neuropharmacol. 29(6), 331-337 (2006). • Compares the effects of quetiapine versus clozapine in 27 patients with PD and onset psychosis.
120. Waseem S, Gwinn-Hardy K. Pain in Parkinson's disease: common yet seldom recognized symptom is treatable. Postgrad. Med. 110, 33-40 (2001).
121. Goetz CG, Tanner CM, Levy M et al. Pain in Parkinson's disease. Mov. Disord. 1(1), 45-49 (1986).
122. Quinn NP, Koller WC, Lang AE et al. Painful Parkinson's disease. Lancet 1, 1366-1369 (1996).
123. Pacchetti C, Albani G, Martignoni E et al. "Off" painful dystonia in Parkinson's disease treated with botulinum toxin. Mov. Disord. 10(3), 333-336 (1995).
124. Hawkes CH, Shephard BC, Daniel SE. Olfactory dysfunction in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 62, 436-446 (1997).
125. Double KL, Rowe DB, Hayes M et al. Identifying the pattern of olfactory deficits in Parkinson disease using the brief smell identification test. Arch. Neurol. 60, 545-549 (2003).
126. Doty RL, Deems DA, Stellar S. Olfactory dysfunction in Parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology 38(8), 1237-1244 (1988).
127. Ansari KA, Johnson A. Olfactory function in patients with Parkinson's disease. J. Chronic Dis. 28, 493-497 (1975).
128. Doty RL, Stern MB, Pfeiffer C, Gollomp SM, Hurtig HI. Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 55, 138-142 (1992).
129. Ponsen MM, Stoffers D, Booij J, van Eck-Smit BL, Wolters ECH, Berendse HW. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann. Neurol. 56, 173-181 (2004).
130. Davidsdottir S, Cronin-Golomb A, Lee A. Visual and spatial symptoms in Parkinson's disease. Vision Res. 45(10), 1285-1296 (2005).
131. Lee AC, Harris JP. Problems with perception of space in Parkinson's disease. Neuroophthalmology 22, 1-15 (1999).